Sequoia Financial Advisors’s GSK GSK Stock Holding History

Sequoia Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	36,293 +641	+2%	+$33.9K	0.01%	649
2026 Q1	$1.97M	Buy	35,652 +1,847	+5%	+$100K	0.01%	603
2025 Q4	$1.66M	Buy	33,805 +1,131	+3%	+$52.8K	0.01%	653
2025 Q3	$1.41M	Buy	32,674 +5,929	+22%	+$232K	0.01%	644
2025 Q2	$1.03M	Buy	26,745 +3,451	+15%	+$132K	0.01%	674
2025 Q1	$902K	Buy	23,294 +2,649	+13%	+$97K	0.01%	659
2024 Q4	$698K	Sell	20,645 -2,292	-10%	-$82.5K	0.01%	694
2024 Q3	$938K	Buy	22,937 +577	+3%	+$23.6K	0.01%	564
2024 Q2	$861K	Buy	22,360 +183	+0.8%	+$7.7K	0.01%	515
2024 Q1	$951K	Buy	22,177 +1,000	+5%	+$41.2K	0.01%	488
2023 Q4	$785K	Buy	21,177 +5,485	+35%	+$197K	0.01%	599
2023 Q3	$569K	Buy	15,692 +1,585	+11%	+$56.3K	0.01%	482
2023 Q2	$503K	Buy	14,107 +363	+3%	+$13K	0.01%	524
2023 Q1	$489K	Buy	13,744 +2,824	+26%	+$98.8K	0.01%	467
2022 Q4	$384K	Buy	+10,920	New	+$364K	0.01%	512
2022 Q3	–	Sell	-10,998	Closed	-$598K	–	560
2022 Q2	$598K	Buy	10,998 +132	+1%	+$7.29K	0.02%	296
2022 Q1	$591K	Buy	10,866 +2,484	+30%	+$135K	0.01%	323
2021 Q4	$462K	Buy	+8,382	New	+$436K	0.01%	339
2021 Q3	–	Sell	-4,599	Closed	-$229K	–	331
2021 Q2	$229K	Buy	+4,599	New	+$221K	0.01%	429
2021 Q1	–	Sell	-4,582	Closed	-$211K	–	455
2020 Q4	$211K	Sell	4,582 -568	-11%	-$26.1K	0.01%	387
2020 Q3	$242K	Buy	5,150 +85	+2%	+$4.26K	0.01%	335
2020 Q2	$258K	Sell	5,065 -124	-2%	-$6.36K	0.02%	311
2020 Q1	$246K	Sell	5,189 -1,171	-18%	-$62.5K	0.02%	298
2019 Q4	$374K	Buy	6,360 +242	+4%	+$13.5K	0.02%	267
2019 Q3	$326K	Sell	6,118 -364	-6%	-$18.7K	0.02%	265
2019 Q2	$324K	Buy	6,482 +784	+14%	+$39.3K	0.02%	268
2019 Q1	$298K	Sell	5,698 -42	-0.7%	-$2.1K	0.02%	267
2018 Q4	$274K	Buy	5,740 +554	+11%	+$27.3K	0.03%	220
2018 Q3	$260K	Sell	5,186 -1,358	-21%	-$69K	0.03%	255
2018 Q2	$330K	Buy	6,544 +144	+2%	+$7.25K	0.04%	211
2018 Q1	$313K	Buy	6,400 +1,171	+22%	+$54.5K	0.03%	227
2017 Q4	$232K	Buy	5,229 +129	+3%	+$5.96K	0.02%	259
2017 Q3	$259K	Sell	5,100 -104	-2%	-$5.28K	0.03%	229
2017 Q2	$281K	Buy	5,204 +4	+0.1%	+$213	0.03%	218
2017 Q1	$274K	Buy	5,200 +687	+15%	+$34.9K	0.03%	216
2016 Q4	$217K	Buy	4,513 +3	+0.1%	+$148	0.03%	250
2016 Q3	$243K	Buy	4,510 +4	+0.1%	+$219	0.05%	199
2016 Q2	$244K	Buy	+4,506	New	+$237K	0.07%	198

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sequoia Financial Advisors's GSK Position: Q2 2026 in Review

Sequoia Financial Advisors increased its GSK (GSK) stake by 1.8% in Q2 2026, buying an estimated $33.9K and bringing the position to 36,293 shares worth $1.9M. The position accounts for 0.01% of the portfolio, ranked #649.

Sequoia Financial Advisors first reported a position in GSK in Q2 2016 and has held it in 38 quarters since. The position peaked at $1.97M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Sequoia Financial Advisors held 36,293 shares of GSK worth $1.9M as of Q2 2026.
Sequoia Financial Advisors bought 641 GSK shares in Q2 2026, an estimated $33.9K.
GSK made up 0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #649 holding.
Sequoia Financial Advisors first reported a position in GSK in Q2 2016 and has held it in 38 quarters since.
Sequoia Financial Advisors's GSK position peaked at $1.97M in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.